Board of Directors

Eric Bednarski, Ph.D.Chairman
Dr. Bednarski is a partner at MVM Life Sciences, a venture capital firm that invests in technologies and products for the life science and healthcare markets, with over $500 million under management. He joined MVM in 2008 from Advent International in Boston where he was involved in several healthcare investments. Prior to Advent, Dr. Bednarski served as a director in the corporate finance group of Silicon Valley Bank. He previously worked in the drug discovery group of Dupont-Merck Pharmaceuticals. Dr. Bednarski holds a Ph.D. in neurobiology from the University of California and a B.S. from Brown University.
David BrandPresident, Founder & Chief Executive Officer, Director
Mr. Brand has more than three decades of pharmaceutical industry experience. Prior to Tarsa, he served as CEO and president of Cardiokine, where he led strategic and organizational development and negotiated a significant global agreement with Biogen Idec for late stage development and marketing of lixivaptan. Previously, Mr. Brand spent over 30 years at GlaxoSmithKline and its predecessor companies. Most recently, he headed the U.S. GI/CNS, product development, metabolic and cardiovascular business units, leading the U.S. launches of Paxil®, Requip® and Avandia®, the pre-launch development of Coreg®, Kytril® and Augmentin® ES/XR, and many co-marketing and licensing deals. Earlier, Mr. Brand held international senior management positions in marketing, acquisitions, business development and regional country management. He holds a bachelor of commerce degree from Concordia University in Montreal.
Martin Edwards, M.D.Director
Dr. Edwards is a senior partner at Novo A/S, a global life science venture capital firm that invests more than $100 million annually. Prior to Novo, Dr. Edwards served as CEO of ReNeuron Holdings, taking the company public in 2000. Earlier, he was corporate vice president and head of drug development for Novo Nordisk A/S. Previously, he served as senior vice president for medical affairs at Novo Nordisk and as vice president of pharmacology and medical affairs of ZymoGenetics. Dr. Edwards currently serves as a director of several life sciences firms and is chairman of Symphogen A/S. He holds degrees in physiology and medicine from Manchester University, as well as post graduate medical diplomas from the London Royal Colleges and an M.B.A. from Warwick University. Dr. Edwards is also adjunct professor of management at the Scandinavian Management Institute (SIMI) in Copenhagen and Copenhagen Business School (CBS).
Richard S. KollenderDirector
Mr. Kollender is a partner at Quaker Partners, a venture capital and growth equity firm investing in healthcare companies.  Previously, he worked at GlaxoSmithKline (GSK), where he held positions of increasing responsibility in sales, marketing and worldwide business development. Mr. Kollender also served as an investment manager at S.R. One, the venture unit of GSK.  He began his career as a certified public accountant with KPMG Peat Marwick and spent six years in public practice, which included an emphasis on healthcare and emerging businesses.  Mr. Kollender serves on the boards of directors of Rapid Micro Biosystems, Celator Pharmaceuticals (Nasdaq: CPXX) and Corridor Pharmaceuticals, and is a board observer for several other Quaker portfolio companies. He holds a B.A. from Franklin and Marshall College and an M.B.A. and Health Administration & Policy degrees with Honors from the University of Chicago.  
Richard LevyDirector
Richard Levy is the Chief Executive Officer and Founder of Victory Park Capital (VPC). He oversees the Firm’s investment and operational activities and is also the Chairman of its Management and Investment Committees.

Mr. Levy serves as Chairman of the Board of Directors of Victory Park portfolio companies EMS Holdings I, Inc., Enteris Biopharma, Inc., Mediterranean Cuisine Holding Company, LLC (Yalla), Surefire Industries USA LLC, VPC Fuller Brush Operating Corp. (The Fuller Brush Company) and VPC Pizza Operating Corp. (Giordano’s). He is also a member of the Board of Directors of VPC portfolio companies Mi Pueblo Food Center, Silver Airways Corp and YR Holdings, LLC.

Previously, Mr. Levy served as head of the Small Cap Structured Products Group and co-head of the Solutions Group at Magnetar Capital. He also co-founded and served as Managing Partner at Crestview Capital Partners.

Mr. Levy received a B.A. in political science from The Ohio State University, an M.B.A. from the Illinois Institute of Technology’s Stuart School of Business and a J.D. from Chicago-Kent College of Law. He is a member of the Illinois bar (inactive). Mr. Levy is also Chairman of the Board of nonprofit, Gardeneers and an active board member of nonprofits College Bound Opportunities and Camp Kesem.

James Tananbaum, M.D.Director
Dr. Tananbaum is the founding CEO of Foresite Capital Management. He has led investments in 21 successful healthcare companies, including Amira Pharmaceuticals (acquired by Bristol-Myers Squibb), Amerigroup and Jazz Pharmaceuticals. Previously, Dr. Tananbaum founded and held management positions at GelTex Pharmaceuticals (acquired by Genzyme for $1.6B) and Theravance. He holds an M.D. from Harvard Medical School and an M.B.A from Harvard Business School, and a B.S. and B.S.E.E. from Yale University. Dr. Tananbaum has served on the advisory boards and/or visiting committees to the Harvard-MIT HST program and Yale School of Engineering.